Royalty Pharma
Stock Forecast, Prediction & Price Target
Royalty Pharma Financial Estimates
Royalty Pharma Revenue Estimates
Royalty Pharma EBITDA Estimates
Royalty Pharma Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $2.28B N/A | $2.23B -2.28% | $2.35B 5.24% | Avg: $2.92B Low: $2.86B High: $2.98B avg. 24.33% | Avg: $3.21B Low: $3.02B High: $3.36B avg. 9.68% | Avg: $3.85B Low: $3.62B High: $4.03B avg. 19.89% | Avg: $4.35B Low: $4.10B High: $4.56B avg. 13.16% |
Net Income
% change YoY
| $478.75M N/A | $42.83M -91.05% | $1.13B 2549.50% | Avg: $1.09B Low: $1.32B High: $1.65B avg. -3.35% | Avg: $1.27B Low: $1.62B High: $1.86B avg. 16.16% | Avg: $3.56B Low: $3.29B High: $3.78B avg. 179.68% | Avg: $4.05B Low: $3.74B High: $4.30B avg. 13.70% |
EBITDA
% change YoY
| $1.48B N/A | $983.16M -33.66% | $1.88B 91.95% | Avg: $2.11B Low: $2.06B High: $2.15B avg. 11.91% | Avg: $2.31B Low: $2.18B High: $2.42B avg. 9.68% | Avg: $2.77B Low: $2.61B High: $2.91B avg. 19.89% | Avg: $3.14B Low: $2.95B High: $3.29B avg. 13.16% |
EPS
% change YoY
| $1.15 N/A | $0.1 -91.49% | $3.41 3386.70% | Avg: $2.48 Low: $2.2 High: $2.75 avg. -27.41% | Avg: $2.92 Low: $2.7 High: $3.1 avg. 17.97% | Avg: $5.91 Low: $5.46 High: $6.28 avg. 102.39% | Avg: $6.72 Low: $6.21 High: $7.14 avg. 13.70% |
Operating Expenses
% change YoY
| $858.74M N/A | $1.31B 53.05% | $862.40M -34.38% | Avg: $251.94M Low: $246.76M High: $257.12M avg. -70.78% | Avg: $276.35M Low: $260.10M High: $289.52M avg. 9.68% | Avg: $331.33M Low: $311.85M High: $347.13M avg. 19.89% | Avg: $374.97M Low: $352.92M High: $392.84M avg. 13.16% |
FAQ
What is Royalty Pharma stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 51.54% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is 1.32B, average is 1.09B and high is 1.65B.
What is Royalty Pharma stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 16.77% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is $2.86B, average is $2.92B and high is $2.98B.
What is Royalty Pharma stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 26.66% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is $2.2, average is $2.48 and high is $2.75.
What is the best performing analyst?
In the last twelve months analysts have been covering Royalty Pharma stock. The most successful analyst is Terence Flynn.